Skip to main content
Top
Published in: BMC Pediatrics 1/2021

Open Access 01-12-2021 | Respiratory Syncytial Virus Infection | Research article

An outbreak of RSV infections in a neonatology clinic during the RSV-season

Authors: Liliya Vakrilova, Stanislava Hitrova Nikolova, Sergei Slavov, Petya Radulova, Boryana Slancheva

Published in: BMC Pediatrics | Issue 1/2021

Login to get access

Abstract

Background

Respiratory syncytial virus (RSV) is the predominant cause of lower respiratory tract infections (LRTI) in infancy. Preterm infants with bronchopulmonary dysplasia (BPD) are at the highest risk of severe RSV-LRTI. This is a retrospective study that analyses a nosocomial outbreak of RSV infections in the Neonatology clinic of the University Hospital of Obstetrics and Gynecology, Sofia, 2019.

Methods

Two groups of infants without contact between them were diagnosed with RSV-infection: 14 infants were treated in the Department for healthy newborns – Group 1, and 7 preterm infants were treated in the Neonatal Intensive Care Unit (NICU) – Group 2. The detection of RSV was performed using Real-Time PCR in nasal/throat swabs.

Results

Respiratory symptoms occurred 2–5 days after discharge in 14 of 148 healthy term infants born February 5 to 18, 2019; 12 babies were re-hospitalized with LRTI and recovered in a few days. RSV-PCR was positive in 6 infants, while in the others, RSV etiology was suggested, due to similar symptoms and contact between them.
The first NICU patient with RSV-LRTI was one of the 26 gestational weeks (GW) twins, who had severe BPD. The other twin was always discharged home without LRTI-symptoms. In the period February 19 to March 15, 2019, 26 premature babies born at 26–34 GW, were tested for RSV (33 nasal/throat swabs). They received a first or subsequent palivizumab injection. We identified 11 positive samples in 7 of the babies. Despite the clinical recovery, the second RSV-PCR remained positive in 4 babies. Six of the 7 NICU patients had symptoms of LRTI, and two of them needed mechanical ventilation. Six babies were discharged home after stabilization, one was transferred to the Pediatric department for further treatment of BPD and later discharged too.

Conclusions

This was the most serious outbreak of RSV infections in neonates since the RSV-PCR diagnostic in Bulgaria was introduced. The course of RSV-LRTI was severe in extremely preterm patients with underlying BPD. So, routine in-hospital RSV-prophylaxis with palivizumab should be considered for infants at the highest risk.
Literature
1.
go back to reference Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999;282(15):1440–6.CrossRef Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999;282(15):1440–6.CrossRef
2.
go back to reference Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588–98.CrossRef Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588–98.CrossRef
3.
go back to reference Shi T, McAllister DA, O'Brien KL, Simoes EAF, Madhi SA, Gessner BD, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modeling study. Lancet. 2017;390(10098):946–58.CrossRef Shi T, McAllister DA, O'Brien KL, Simoes EAF, Madhi SA, Gessner BD, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modeling study. Lancet. 2017;390(10098):946–58.CrossRef
7.
go back to reference Blanken MO, Paes B, Anderson EJ, Lanari M, Sheridan-Pereira M, Buchan S, et al. Risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants. Pediatr Pulmonol. 2018;53(5):605–12.CrossRef Blanken MO, Paes B, Anderson EJ, Lanari M, Sheridan-Pereira M, Buchan S, et al. Risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants. Pediatr Pulmonol. 2018;53(5):605–12.CrossRef
8.
go back to reference Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JL, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368(19):1791–9 Erratum in: N Engl J Med. 2016;374(24):2406.CrossRef Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JL, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368(19):1791–9 Erratum in: N Engl J Med. 2016;374(24):2406.CrossRef
9.
go back to reference Resch B. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection. Hum Vaccin Immunother. 2017;13(9):2138–49.CrossRef Resch B. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection. Hum Vaccin Immunother. 2017;13(9):2138–49.CrossRef
11.
go back to reference Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102(3 Pt 1):531–7. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102(3 Pt 1):531–7.
12.
go back to reference Torchin H, Rousseau J, Marchand-Martin L, Truffert P, Jarreau PH, Ancel PY. Palivizumab administration in preterm infants in France: EPIPAGE-2 cohort study. Arch Pediatr. 2018;25(2):89–94.CrossRef Torchin H, Rousseau J, Marchand-Martin L, Truffert P, Jarreau PH, Ancel PY. Palivizumab administration in preterm infants in France: EPIPAGE-2 cohort study. Arch Pediatr. 2018;25(2):89–94.CrossRef
13.
go back to reference Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, et al. Cardiac Synagis study group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143(4):532–40.CrossRef Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, et al. Cardiac Synagis study group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143(4):532–40.CrossRef
14.
go back to reference Anderson EJ, Carosone-Link P, Yogev R, Yi J, Simões EAF. Effectiveness of Palivizumab in high-risk infants and children: a propensity score weighted regression analysis. Pediatr Infect Dis J. 2017;36(8):699–704.CrossRef Anderson EJ, Carosone-Link P, Yogev R, Yi J, Simões EAF. Effectiveness of Palivizumab in high-risk infants and children: a propensity score weighted regression analysis. Pediatr Infect Dis J. 2017;36(8):699–704.CrossRef
15.
go back to reference Korsun N, Angelova S, Tzotcheva I, Georgieva I, Lazova S, Parina S, et al. Prevalence and genetic characterization of respiratory syncytial viruses circulating in Bulgaria during the 2014/15 and 2015/16 winter seasons. Pathog Glob Health. 2017;111(7):351–61.CrossRef Korsun N, Angelova S, Tzotcheva I, Georgieva I, Lazova S, Parina S, et al. Prevalence and genetic characterization of respiratory syncytial viruses circulating in Bulgaria during the 2014/15 and 2015/16 winter seasons. Pathog Glob Health. 2017;111(7):351–61.CrossRef
16.
go back to reference Korsun N, Angelova S, Trifonova I, Georgieva I, Voleva S, Tzotcheva I, et al. Viral pathogens associated with acute lower respiratory tract infections in children younger than 5 years of age in Bulgaria. Braz J Microbiol. 2019;50(1):117–25.CrossRef Korsun N, Angelova S, Trifonova I, Georgieva I, Voleva S, Tzotcheva I, et al. Viral pathogens associated with acute lower respiratory tract infections in children younger than 5 years of age in Bulgaria. Braz J Microbiol. 2019;50(1):117–25.CrossRef
17.
go back to reference Carande EJ, Pollard AJ, Drysdale SB. Management of Respiratory Syncytial Virus Bronchiolitis: 2015 survey of members of the European Society for Paediatric Infectious Diseases. Can J Infect Dis Med Microbiol 2016;2016:9139537. https://doi.org/10.1155/2016/9139537. Carande EJ, Pollard AJ, Drysdale SB. Management of Respiratory Syncytial Virus Bronchiolitis: 2015 survey of members of the European Society for Paediatric Infectious Diseases. Can J Infect Dis Med Microbiol 2016;2016:9139537. https://​doi.​org/​10.​1155/​2016/​9139537.
18.
go back to reference Kodani M, Yang G, Conklin LM, Travis TC, Whitney CG, Anderson LJ, et al. Application of TaqMan low-density arrays for simultaneous detection of multiple respiratory pathogens. J Clin Microbiol. 2011;49(6):2175–82.CrossRef Kodani M, Yang G, Conklin LM, Travis TC, Whitney CG, Anderson LJ, et al. Application of TaqMan low-density arrays for simultaneous detection of multiple respiratory pathogens. J Clin Microbiol. 2011;49(6):2175–82.CrossRef
19.
go back to reference Calvo C, Pozo F, García-García ML, Sanchez M, Lopez-Valero M, Pérez-Breña P, et al. Detection of new respiratory viruses in hospitalized infants with bronchiolitis: a three-year prospective study. Acta Paediatr. 2010;99(6):883–7.CrossRef Calvo C, Pozo F, García-García ML, Sanchez M, Lopez-Valero M, Pérez-Breña P, et al. Detection of new respiratory viruses in hospitalized infants with bronchiolitis: a three-year prospective study. Acta Paediatr. 2010;99(6):883–7.CrossRef
20.
go back to reference Esposito S, Daleno C, Prunotto G, Scala A, Tagliabue C, Borzani I, et al. Impact of viral infections in children with community-acquired pneumonia: results of a study of 17 respiratory viruses. Influenza Other Respir Viruses. 2013;7(1):18–26.CrossRef Esposito S, Daleno C, Prunotto G, Scala A, Tagliabue C, Borzani I, et al. Impact of viral infections in children with community-acquired pneumonia: results of a study of 17 respiratory viruses. Influenza Other Respir Viruses. 2013;7(1):18–26.CrossRef
21.
go back to reference Mazur NI, Martinón-Torres F, Baraldi E, Fauroux B, Greenough A, Heikkinen T, et al. Respiratory syncytial virus network (ReSViNET). Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir Med. 2015;3(11):888–900.CrossRef Mazur NI, Martinón-Torres F, Baraldi E, Fauroux B, Greenough A, Heikkinen T, et al. Respiratory syncytial virus network (ReSViNET). Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir Med. 2015;3(11):888–900.CrossRef
22.
go back to reference Committee on Infectious Diseases. From the American Academy of Pediatrics: policy statements--modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124(6):1694–701.CrossRef Committee on Infectious Diseases. From the American Academy of Pediatrics: policy statements--modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124(6):1694–701.CrossRef
23.
go back to reference American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection [published correction appears in Pediatrics. 2014;134(6):1221]. Pediatrics. 2014;134(2):415–20.CrossRef American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection [published correction appears in Pediatrics. 2014;134(6):1221]. Pediatrics. 2014;134(2):415–20.CrossRef
24.
go back to reference Belleudi V, Trotta F, Pinnarelli L, Davoli M, Addis A. Neonatal outcomes following new reimbursement limitations on palivizumab in Italy. Arch Dis Child. 2018;103(12):1163–7.CrossRef Belleudi V, Trotta F, Pinnarelli L, Davoli M, Addis A. Neonatal outcomes following new reimbursement limitations on palivizumab in Italy. Arch Dis Child. 2018;103(12):1163–7.CrossRef
25.
go back to reference Meissner HC, Kimberlin DW. RSV immunoprophylaxis: does the benefit justify the cost? Pediatrics. 2013;132(5):915–8.CrossRef Meissner HC, Kimberlin DW. RSV immunoprophylaxis: does the benefit justify the cost? Pediatrics. 2013;132(5):915–8.CrossRef
26.
go back to reference Ginsberg GM, Somekh E, Schlesinger Y. Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? - a cost-utility analysis. Isr J Health Policy Res. 2018;7(1):63.CrossRef Ginsberg GM, Somekh E, Schlesinger Y. Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? - a cost-utility analysis. Isr J Health Policy Res. 2018;7(1):63.CrossRef
27.
go back to reference Drysdale SB, Green CA, Sande CJ. Best practice in the prevention and management of pediatric respiratory syncytial virus infection. Ther Adv Infect Dis. 2016;3(2):63–71.PubMedPubMedCentral Drysdale SB, Green CA, Sande CJ. Best practice in the prevention and management of pediatric respiratory syncytial virus infection. Ther Adv Infect Dis. 2016;3(2):63–71.PubMedPubMedCentral
34.
go back to reference Saadah LM, Chedid FD, Sohail MR, Nazzal YM, Al Kaabi MR, Rahmani AY. Palivizumab prophylaxis during nosocomial outbreaks of respiratory syncytial virus in a neonatal intensive care unit: predicting effectiveness with an artificial neural network model. Pharmacotherapy. 2014;34(3):251–9. https://doi.org/10.1002/phar.1333.CrossRefPubMed Saadah LM, Chedid FD, Sohail MR, Nazzal YM, Al Kaabi MR, Rahmani AY. Palivizumab prophylaxis during nosocomial outbreaks of respiratory syncytial virus in a neonatal intensive care unit: predicting effectiveness with an artificial neural network model. Pharmacotherapy. 2014;34(3):251–9. https://​doi.​org/​10.​1002/​phar.​1333.CrossRefPubMed
40.
go back to reference Saso A, Kampmann B. Vaccination against respiratory syncytial virus in pregnancy: a suitable tool to combat global infant morbidity and mortality? Lancet Infect Dis. 2016;16(8):e153–63.CrossRef Saso A, Kampmann B. Vaccination against respiratory syncytial virus in pregnancy: a suitable tool to combat global infant morbidity and mortality? Lancet Infect Dis. 2016;16(8):e153–63.CrossRef
41.
go back to reference Giersing BK, Karron RA, Vekemans J, Kaslow DC, Moorthy VS. Meeting report: WHO consultation on respiratory syncytial virus (RSV) vaccine development, Geneva, 25-26 April 2016. Vaccine. 2019;37(50):7355–62.CrossRef Giersing BK, Karron RA, Vekemans J, Kaslow DC, Moorthy VS. Meeting report: WHO consultation on respiratory syncytial virus (RSV) vaccine development, Geneva, 25-26 April 2016. Vaccine. 2019;37(50):7355–62.CrossRef
42.
go back to reference Vekemans J, Moorthy V, Giersing B, Friede M, Hombach J, Arora N, et al. Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics. Vaccine. 2019;37(50):7394–5.CrossRef Vekemans J, Moorthy V, Giersing B, Friede M, Hombach J, Arora N, et al. Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics. Vaccine. 2019;37(50):7394–5.CrossRef
43.
go back to reference Rezaee F, Linfield DT, Harford TJ, Piedimonte G. Ongoing developments in RSV prophylaxis: a clinician's analysis. Curr Opin Virol. 2017;24:70–8 r Opin Virol. 2017;24:70-8.CrossRef Rezaee F, Linfield DT, Harford TJ, Piedimonte G. Ongoing developments in RSV prophylaxis: a clinician's analysis. Curr Opin Virol. 2017;24:70–8 r Opin Virol. 2017;24:70-8.CrossRef
Metadata
Title
An outbreak of RSV infections in a neonatology clinic during the RSV-season
Authors
Liliya Vakrilova
Stanislava Hitrova Nikolova
Sergei Slavov
Petya Radulova
Boryana Slancheva
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Pediatrics / Issue 1/2021
Electronic ISSN: 1471-2431
DOI
https://doi.org/10.1186/s12887-021-03053-9

Other articles of this Issue 1/2021

BMC Pediatrics 1/2021 Go to the issue